LongRVXer - I hear you and generally agree with you view however... The 22% or 25% of dilution over the past year is enough to make me throw up however I do see the potential benefit to Zenith by continuing these loans to RVX. If RVX is actually able to get apabetalone on the market for long COVID or for cardio or both Zenith and its shareholders would do well(or have the potential to do well) from the royalties that would be generated from those sales. 

As far as I'm aware there are no treatments for long COVID at this time and having a couple of hundred million patients waiting might just work in our favour. Being oh so aware of the lack of achievements of this management team does kind of scare the p#@p out of me though. My hope is that if approval is ever earned Eversana is able to take the reins and let thoughts horses run like the wind.

This is definitely a case of " are those royalty preferred shares a blessing or a curse"

tada